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Background/aim: The presence of comorbidities in patients with acromegaly causes an increase in morbidity and/or mortality and a
decrease in quality of life. In this study, we aimed to investigate the demographic, clinical and laboratory features, prevalence of acromegaly-related comorbidities, and factors associated with these comorbidities in patients with acromegaly.
Materials and methods: In the study, 96 patients who were followed up with the diagnosis of acromegaly were included. Clinical, laboratory and imaging features, and accompanying comorbidities of the patients were recorded from the patient files.
Results: Of the patients included in the study, 63 (65.6%) were female and 33 (34.4%) were male. The mean age of diagnosis was 42.61±
12.08, and the mean follow-up period was 9.97 ± 7.26 years. Median insulin-like growth factor 1 level was 238.16 ng/mL (30.5–820),
median growth hormone level was 2.05 ug/L (0.1–29.4). A total of 60 (62.5%) of the patients were in the well-controlled group, and
36 (37.5%) had active disease at the time of inclusion. Diabetes mellitus (DM) was detected in 30 (31.3%) patients, prediabetes in 19
(28.8%) patients, hypertriglyceridemia in 38 (42.2%) patients, hypertension (HT) in 41 (42.7%) patients, cardiovascular disease in 5
(5.2%) patients, malignancy in 9 (9.4%) patients, obstructive sleep apnea syndrome in 8 (8.3%) patients, carpal tunnel syndrome in
11 (11.5%) patients, arthropathy in 5 (5.2%) patients, hearing loss in 7 (7.3%) patients, thyroid nodule in 56 (67.5%) patients, thyroid
cancer in 4 (4.2%) patients, colonic polyp in 19 (38.8%) patients.
Conclusion: In this study, we revealed that the most common comorbidities in acromegaly patients in the Turkish population are
thyroid nodules, low high-density lipoprotein (HDL cholesterol (HDL-C) level, hypertriglyceridemia, HT, colonic polyps, DM, and
prediabetes, and female sex and age at diagnosis are the most important factors associated with comorbidities.
Key words: Acromegaly, comorbidity, growth hormone, insulin-like growth factor 1

1.Introduction
Acromegaly is a rare, chronic disease characterized by
increased growth hormone (GH) and insulin-like growth
factor 1 (IGF-1) levels, mostly caused by GH secreting
pituitary adenoma.
Although acromegaly is a rare disease, its associated
comorbidities and the required lifetime management mean
that acromegaly can be a large burden [1]. Long-term
presence of increased GH and IGF-1 levels in acromegaly
is associated with complications, such as diabetes mellitus
(DM), cardiovascular disease (CVD), obstructive sleep
apnea syndrome (OSAS), increased mortality especially
due to CVD and cancer, impaired quality of life, and low
life expectancy [2]. Since the time from onset of symptoms
to diagnosis is approximately 4.5 to 5 years in acromegaly,
complications are common both during and after diagnosis.

In this study, we aimed to investigate the demographic,
clinical, laboratory and imaging features, disease
activity status, therapies they received, the prevalence
of comorbidities, and the factors associated with
comorbidities in patients followed up with the diagnosis
of acromegaly.
2.Materials and methods
96 patients over 18 years old who were followed up with
the diagnosis of acromegaly between January 2006 and
January 2020 in the Necmettin Erbakan University School
of Medicine Department of Endocrinology were included
in the study. Necmettin Erbakan University, School of
Medicine Ethics Committee approved the study with the
approval number of 2020/2511 and the date of 22.05.2020.
The demographic, clinical, laboratory data of the patients
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were recorded from the patient files. Patients with a family
history of cancer, especially thyroid and colon cancer, and
a history of radiotherapy to the head and neck region for
reasons other than acromegaly were excluded from the
study.
A normal IGF-1 level in terms of age and sex and lack
of suppression of GH to 0.4 ng/mL following documented
hyperglycemia during an oral glucose load or random
GH level <1 ng/mL were determined as criteria for being
included in the “well-controlled” group. Those who did
not meet these criteria were included in the “active disease”
group.
The imaging features of the patients evaluated by
magnetic resonance imaging (MRI) were recorded
from their files. Pituitary adenomas less than 10 mm in
diameter were considered as microadenomas, adenomas
with a diameter of 10 mm and larger were considered as
macroadenoma. Patients who met any of the following
criteria were considered to have DM: fasting plasma
glucose (FPG) ≥ 126 mg/dL or 75 gram oral glucose
tolerance test (OGTT) 2nd h plasma glucose ≥ 200 mg/dL
or random plasma glucose ≥ 200 mg/dL in a person with
diabetes symptoms or HbA1C≥6.5%. Patients with FPG
between 100–125 mg/dL (ımpaired fasting glucose-IFG)
or OGTT 2nd h PG between 140–199 mg/dL (ımpaired
glucose tolerance-IGT) or HbA1C 5.7-6.4% were
considered to have prediabetes. Patients with triglyceride ≥
150 mg/dL were considered to have hypertriglyceridemia,
and patients with high density lipoprotein cholesterol
(HDL-C) < 40 mg/dL for men and HDL-C < 50 mg/dL
for women were considered to have low HDL-C. Lesions
larger than 3 mm were considered as nodules in thyroid
ultrasonography (US). Patients whose nerve conduction
study/electromyography findings were consistent with
CTS were considered to have carpal tunnel syndrome
(CTS). Patients with cardiovascular disease proven by
methods, such as electrocardiography, echocardiography
and coronary angiography, were considered to have CVD.
Patients whose polysomnograhy results were compatible
with OSAS were considered to have OSAS. Those
determined to have conductive, sensorineural, or mixed
type hearing loss as a result of audiometry measurements
were considered to have hearing loss. Those who had
arthropathy confirmed by imaging methods (X-ray, MRI)
but did not have other arthropathy causes (rheumatoid
arthritis, psoriatic arthritis etc.) were considered to have
arthropathy.
2.1.Statistical analysis
Statistical analysis were performed using the SPSS 22.0
(IBM Corp., Armonk, NY, USA) program. Continuous
variables were given as mean ± standard deviation when
the distribution was normal and median (minimummaximum) when it was nonnormal. To compare the

independent group differences, the significance test of the
difference between the two means (independent samples
t test) was used if there were parametric test assumptions;
if there are no parametric test assumptions, the Mann–
Whitney U test was used. Pearson’s correlation coefficient
was used for correlation analysis between numerical
variables with normal distribution, and Spearman test was
used for correlation analysis between numerical variables
that did not show normal distribution. The chi-squared test
was used to evaluate the differences between categorical
variables. For differences, P value <0.05 was considered
statistically significant.
3.Results
Of the patients included in the study, 63 (65.6%) were
female and 33 (34.4%) were male. The mean age of
the patients was 42.61 ± 12.08 years at the time of the
diagnosis of the acromegaly, and the median follow-up
was 9.97 ± 7.26 years. The median IGF-1 level was 238.16
ng/mL (30.5–820), and the median GH level was 2.05
ug/L (0.1–29.4) (Table 1). A total of 33 of the patients had
microadenoma and 63 had macroadenoma. Two patients
had hyperprolactinemia accompanying acromegaly.
A total of 93 patients had undergone surgical
treatment, and medical treatment was started as the
primary treatment modality in 3 patients who refused
surgical treatment. Radiotherapy (RT) was applied to
29 patients and 14 (48.3%) of the patients who received
radiotherapy were in remission. Forty-six patients were
on medical treatment at the time of inclusion, of which 27
were on somatostatin receptor ligand (SRL) and 19 were on
cabergoline treatment. 9 (33.3%) of 27 patients who were
on SRL were in remission, and 6 (31.6%) of 19 patients
who were on cabergoline were in remission. A total of 60
(62.5%) patients were in the well controlled group, and 36
(37.5%) patients had active disease.
Of the 36 patients in the active disease group, 23 were
female and 13 were male. The mean age at diagnosis of
36 patients in the active disease group was 43.51 ± 12.66,
and the mean follow-up period was 9.83 ± 8,02 years. The
median IGF-1 level in the active disease group was 402.07
ng/mL (202.9–820), and the median GH level was 4.02
ug/L (0.6–29.4) (Table 1). A total of 8 of the patients had
microadenoma and 28 had macroadenoma. In the active
disease group, 16 (44.4%) patients were on SRL, 5 (13.9%)
patients were on cabergoline, and 1 (2.8%) was on SRL
plus cabergoline.
Of the 60 patients in the well controlled group, 40 were
female and 20 were male. The mean age at diagnosis of 60
patients in the well controlled group was 42.10 ± 11.81,
and the mean follow-up period was 10.05 ± 6.85 years.
The median IGF-1 level in the well controlled group was
144.94 ng/mL (30.5–332.4), and the median GH level was
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Table 1. Demographic characteristics, complications and comorbidity prevalence of patients according to groups.
All acromegaly population

Active disease group

Well-controlled group

Age of diagnosis (years)

42.61± 12.08

43.51 ± 12.66

42.10 ± 11.81

P
0.230

Sex (female/male)

63/33

23/13

40/20

0.977

Follow-up time (years)

9.97 ± 7.26

9,83± 8,02

10.05 ± 6.85

0.390

IGF-1 (ng/mL)

238.16 (30.5–820)

402.07 (202.9–820)

144.94(30.5–332.4)

< 0.001

GH (ug/L)

2.05 (0.1–29.4)

4.02 (0.6–29.4)

0.918 (0.1–7.9)

< 0.001

Adenom size (micro/macro)

33/63

8/28

25/35

0,023

DM n (%)

30/96 (31.3)

16/36 (44.4)

14 (23.3)

0.007

Prediabetes n (%)

19/66 (28.8)

8/20 (40.0)

11 (23.9)

0.851

Hypertriglyceridemia n (%)

38/90 (42.2)

16/35 (45.7)

22/55 (40.0)

0.480

Low HDL-C n (%)

44/90 (48.9)

15/35 (42.9)

29/55 (52.7)

0.480

HT n (%)

41/96 (42.7)

16/36 (44.4)

25/60 (41.7)

0.437

CVD n (%)

5/96 (5.2)

2/36 (5.6)

3/60 (5)

0.993

Malignancy n (%)

9/96 (9.4)

3/36 (8.3)

6/60 (10)

0.871

OSAS n (%)

8 /96 (8.3)

4/36 (11.1)

4/60 (6.7)

0.882

CTS n (%)

11/96 (11.5)

3/36 (8.3)

8/60 (13.3)

0.355

Arthropathy n (%)

5/96 (5.2)

0 (0.0)

5/60 (8.3)

0.149

Hearing loss n (%)

7/96 (7.3)

3/36 (8.3)

4/60 (6.7)

0.447

Thyroid nodule n (%)

56/83 (67.5)

23/32 (71.9)

33/51 (64.7)

0.476

Thyroid cancer n (%)

4/83 (4.2)

1/32 (2.8)

3/51 (5.9)

0.577

Colonic polyp n (%)

19/49 (38.8)

8/20(40)

11/29 (37.9)

0.960

IGF-1: insulin-like growth factor 1; GH: growth hormone; DM: diabetes mellitus; HDL-C: high density lipoprotein cholesterol; HT:
hypertension; CVD: cardiovascular disease; OSAS: obstructive sleep apnea syndrome; CTS: carpal tunnel syndrome.

0.918 ug/L (0.1–7.9) (Table 1). A total of 25 of the patients
had microadenoma and 36 had macroadenoma.
In terms of metabolic complications in all acromegaly
patients, 30 (31.3%) patients had DM, 19 (28.8%)
patients had prediabetes, 38 (42.2%) patients had
hypertriglyceridemia, and 44 (48.9%) patients had low
HDL-C levels. As cardiovascular complications, 41
(42.7%) patients had HT and 5 (5.2%) patients had CVD
(atrial fibrillation in 2 patients, coronary artery disease
in 2 patients, cardiomyopathy in 1 patient). Nine (9.4%)
patients had malignancy and papillary thyroid cancer
observed in 4 (4.2%) patients was the most common
malignancy. And there were one (1.04%) patient with
each diagnosis of myelodysplastic syndrome, basal cell
carcinoma, lymphoma, meningioma, and renal cell
carcinoma. In terms of other comorbidities, 8 (8.3%)
patients had OSAS, 11 (11.5%) patients had carpal tunnel
syndrome (CTS), 5 (5.2%) had arthropathy, and 7 (7.3%)
had hearing loss. Thyroid nodules were detected in 56
(67.5%) of 83 patients who underwent thyroid US. Thyroid
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cancer was detected in 4 (4.2%) patients. Colonic polyp
was detected in 19 (38.8%) of 49 patients who underwent
colonoscopy. 4 (4.2%) of the patients had hypopituitarism
(2 panhypopituitarism, 1 central hypothyroidism plus
central hypogonadism, 1 central hypogonadism) in the
preoparative period due to the mass effect of adenoma
(Table 1). Twenty-five patients were on antidiabetic,
12 patients were on antilipidemic, 38 patients were on
antihypertensive medication.
In active disease group, IGF-1 level (P < 0.001), GH
level (P < 0.001), presence of macroadenoma (P = 0.023)
and presence of DM diagnosis (P = 0.02) were higher
than well controlled group (Table 1). Other demographic
parameters and complications were similar between
groups.
In the correlation analysis, we found correlations
between DM and age at diagnosis (r = –0.309, P = 0.002),
female sex (r = 0.204, P = 0.046) and having active disease
(r = 0.236, P = 0.020); between low HDL-C and female
sex (v -0.385, P = 0.001); between hypertension and age at
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diagnosis (r = -0.551, P = 0.001), female sex (r: 0.270, P =
0.008) and adenoma size (r = –0.218, P = 0.033); between
OSAS and age at diagnosis (r = –0.266, P = 0.009); between
malignancy and female sex (r = 0.203, P = 0.047); between
thyroid nodule and age at diagnosis (r = –0.307, P = 0.005);
between colonic polyp and age at diagnosis (r = –0.367, P
= 0.011) (Table 2). There was no significant relationship
between the duration of the disease and the frequency of
comorbidities (Table 2).
4.Discussion
In this study, we found that the most common comorbidities
in acromegaly patients in the Turkish population are
thyroid nodule, low HDL-C level, hypertriglyceridemia,
HT, colonic polyp, DM, and prediabetes. Our study
revealed that the most important factors associated with
comorbidities are female sex and age at diagnosis; only
DM is more common in the active disease group than
the well-controlled group, and the frequencies of other
comorbidities are similar between the groups.
Glucose metabolism disorders, such as DM and
prediabetes are common in patients with acromegaly.
Presence of DM in acromegaly patients is an important
predictive factor for increased mortality [3]. In a
retrospective study, Kreze et al. reported the DM prevalence
as 19% and the impaired glucose tolerance prevalence as
5%. The authors also found that the risk factors associated
with DM and impaired glucose tolerance are family
history of DM and HT, female sex, concomitant prolactin
hypersecretion, and untreated active disease [4]. In another
retrospective study, Biering et al. found DM prevalence as
40.5%, impaired glucose tolerance prevalence as 28.2%
and reported that DM is more common in female patients
[5]. In our study, the prevalence of DM was 31.3%, the
prevalence of prediabetes was 28.8%, and we showed that
the risk factors for DM are female sex, age at diagnosis,

having active disease. In our study, we also showed that
DM prevalence is more frequent in the active disease
group than in the well-controlled group.
Increased circulating levels of lipoprotein-A,
apolipoprotein-A1, and apolipoprotein-E as a result
of insulin resistance in acromegaly leads to disorders
of lipoprotein metabolism. The most common
lipid metabolism disorders in acromegaly are
hypertriglyceridemia and low HDL-C level. Ciresi et al.
found the prevalence of hypertriglyceridemia as 33.2%
and the prevalence of low HDL-C as 39.1%, and also found
that the prevalence of low HDL-C is higher in women
(especially postmenopausal) than men [6]. Møller et al.
identified compensatory hyperinsulinemia as a risk factor
associated with hypertriglyceridemia [7]. In our study,
hypertriglyceridemia prevalence was 42.2%, low HDL-C
prevalence was 48.9%, and sex was found as the factor
associated with low HDL-C.
HT is one of the most common cardiovascular
comorbidities in patients with acromegaly. In a
metaanalysis of 18 series including 2562 patients, the
prevalence of hypertension was reported to be around
35% [8]. Jaffrain-Rea et al. showed that the risk factors
associated with HT are the degree of glucose tolerance
abnormalities and the age of the patient [9]. Other
cardiovascular complications that can be seen in patients
with acromegaly are cardiomyopathy, valvulopathy,
arrhythmias, and atherosclerotic cardiovascular diseases
caused by vascular endothelial dysfunction. Symptomatic
CVD is seen in approximately 20% of patients with
acromegaly [10]. In our study, we found the prevalence
of HT as 42.7% and the prevalence of CVD as 5.2%.
Additionally, the risk factors associated with HT were sex,
age at diagnosis, and adenoma size.
Respiratory complications associated with acromegaly
usually include sleep apnea, sleep respiratory disorders,

Table 2. Correlation analysis of parameters associated with the prevalence of comorbidities.
DM
r = –0.309
Age of diagnosis
P = 0.002
r = 0.015
Follow-up time
P = 0.877
r = 0.204
Female sex
P = 0.046
r = 0.236
Active disease
P = 0.020
r = –0.127
Adenom size
P = 0.217

Low HDL-C
r = 0.099
P = 0.355
r = –0.035
P = 0.740
r = –0.385
P = 0.001
r = 0.008
P = 0.938
r = 0.123
P = 0.247

HT
r = –0.551
P = 0.001
r = 0.098
P = 0.341
r = 0.270
P = 0.008
r = –0.046
P = 0.656
r = –0.218
P = 0.033

OSAS
r = –0.266
P = 0.009
r = 0.110
P = 0.285
r = –0.050
P = 0.628
r = 0.037
P = 0.718
r = 0.034
P = 0.740

Malignancy
r = 0.014
P = 0.889
r = –0.142
P = 0.167
r = 0.203
P = 0.047
r =– 0.046
P = 0.657
r = 0.119
P = 0.250

Thyroid nodule
r = –0.307
P = 0.005
r = 0.010
P = 0.927
r = 0.050
P = 0.654
r = 0.055
P = 0.624
r = –0.136
P = 0.219

Colonic polyp
r = –0.367
P = 0.011
r = –0.086
P = 0.565
r = –0.232
P = 0.117
r = 0.028
P = 0.151
r = –0.214
P = 0.149

DM: diabetes mellitus; HDL-C: high density lipoprotein cholesterol; HT: hypertension; OSAS: obstructive sleep apnea syndrome.
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and respiratory failure [11]. Causes of respiratory
complications associated with acromegaly include
decreased lung flexibility, changes in respiratory mucosa
and cartilage, anatomical abnormalities that affect
craniofacial bones and soft tissues. Acromegaly is generally
associated with obstructive sleep apnea syndrome (OSAS)
arising from anatomical abnormalities. In a prospective
study, Davi et al. found the prevalence of sleep apnea
in the entire acromegaly population, in the group with
active disease, and in the group in which the disease was
in remission, respectively, as 47%, 56%, and 39%. The
authors also reported that the factors associated with sleep
apnea were age, male sex, IGF1, body mass index (BMI),
and disease duration [12]. In our study, we found that the
prevalence of OSAS is 8.3%, the factor associated with
OSAS is age at diagnosis.
There are several clinical studies and animal studies
showing that high IGF-1 and GH levels are associated with
cancer development and progression [13]. In most studies,
patients with acromegaly have been reported to have a
moderately increased risk for developing thyroid, colon,
breast, hematological, and prostate cancer. In retrospective
studies in patients with acromegaly, the prevalence
of malignancy was found to be 6.3 to 14% [14,15]. In a
prospective study, Baris et al. reported that gastrointestinal
tract (small intestine, colon), brain, thyroid, kidney,
and bone cancers are the most common cancer types in
acromegaly [14]. In a retrospective study, Kurimoto et al.
reported that colon, thyroid, breast, and gastric cancer are
the most common in patients with acromegaly [15]. In our
study, we found the malignancy prevalence as 8.3% and
was similar to previous studies. However, unlike previous
studies, we found thyroid cancer as the most common
cancer type in our study. We found female sex as the only
risk factor associated with malignancy.
A common complication associated with acromegaly
is CTS. The main cause of median nerve neuropathy in
patients with acromegaly is edema of the median nerve
in the carpal tunnel [16]. Oktayoglu et al. reported the
prevalence of CTS as 50% in patients with acromegaly
[17]. In our study, the prevalence of CTS was found to be
11.5%, and we did not determine a risk factor associated
with CTS.
Arthropathy is common in patients with acromegaly.
In acromegaly patients, arthropathy is thought to be due to
two mechanisms, initially GH and IGF-1 excess, and later
mechanical changes [18]. In a prospective study of Kropf et
al., the prevalence of arthropathy was reported to be 56%
in patients with acromegaly [19]. They found increased
BMI, advanced age, and female sex as factors associated
with arthropathy. In our study, we found the prevalence
of arthropathy as 5.2%, and we did not determine a risk
factor associated with arthropathy.
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Hearing loss is common in patients with acromegaly.
Although the cause of hearing loss in acromegaly is
not fully known, it is thought to be caused by soft
tissue enlargement and bony hypertrophy. Aydin et al.
performed a prospective study of acromegaly patients;
hearing loss was found to be 43% [20]. In our study, we
found the prevalence of hearing loss as 7.3% and we did
not determine a risk factor associated with hearing loss.
Thyroid nodules are common in patients with
acromegaly. IGF-1 stimulates protein and deoxyribonucleic
acid synthesis in tyrosides and leads to cell proliferation
and differentiation [21]. Prolonged exposure to high
serum IGF-1 levels in acromegaly is thought to lead to the
development of thyroid nodules [22]. In the meta-analysis
of Wolinski et al., thyroid nodule and thyroid cancer
prevalences were reported as 59.2% and 4.3%, respectively
[21]. In retrospective studies in patients with acromegaly,
the prevalence of thyroid cancer has been reported to be
1 to 3% [22]. In our study, we found thyroid nodule and
thyroid cancer prevalences as 67.5% and 4.2%, respectively.
In our study, we found age at diagnosis as factors related to
thyroid nodules. We did not find a factor associated with
thyroid cancer.
Both benign and malignant colon lesions are frequently
encountered in patients with acromegaly. Prolonged
exposure to high GH and IGF-1 levels is thought to play a
role in the pathogenesis of the development of colon lesions
[23]. In addition, it is thought that the continuous high
levels of GH and IGF1 may facilitate the growth of preexisting colon tumors [24]. Kurimoto et al. retrospective
study reported that colon polyp prevalence was 40.2%,
and colon cancer prevalence was 10.3% in patients with
acromegaly [15]. Another retrospective study reported the
prevalence of hyperplastic polyp, adenomatous polyp and
colon cancer in patients with acromegaly as 19.1%, 23.4%,
and 4.3%, respectively [25]. In our study, the prevalence
of colonic polyp (38.8%) was similar to previous studies.
In our study, we found age at diagnosis as a factor related
to colonic polyp. In our study, there was no patient with
colon cancer.
When we compare our results with previous studies,
we noticed that hypertriglyceridemia, low HDL-C, and
thyroid nodule prevalences were higher than previous
studies, DM, prediabetes, HT, malignancy, and colonic
polyp prevalences were similar to previous studies,
while CVD, OSAS, CTS, arthropathy, and hearing loss
prevalences were lower than previous studies.
Our study had some limitations. First, our study
population was limited. Secondly, since our study was a
retrospective study, not all complications were evaluated
in all patients. Presumably due to these limitations, the
prevalences of comorbidities, such as DM, prediabetes,
hypertriglyceridemia, low HDL-C, HT, malignancy,
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thyroid nodule, colonic polyp were similar to or lower than
previous studies, whereas prevalences of comorbidities
such as CVD, OSAS, CTS, arthropathy, and hearing loss
were very low.
In conclusion, regular follow-up of all complications,
particularly malignancies, metabolic, and cardiovascular
complications, is required in all patients to improve
morbidity and mortality in acromegaly patients.
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